3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
2
Sarcoma
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
80
Radiotherapy
41
Bevacizumab
35
Radiosurgery
23
Magnetic Resonance Spectroscopy
20
Cyclophosphamide
17
Radiation
14
Irinotecan
13
Carboplatin
12
Topotecan
11
Nivolumab
11
Lomustine
11
Filgrastim
10
Everolimus
10
Etoposide
10
Erlotinib Hydrochloride
10
pembrolizumab
9
Radiotherapy, Intensity-Modulated
9
Ipilimumab
9
Granulocyte Colony-Stimulating Factor
8
Carmustine
8
antineoplaston AS 2-1
7
antineoplaston A10
7
Surgical Procedures, Operative
7
Mental Status and Dementia Tests
7
Isotretinoin
7
Granulocyte-Macrophage Colony-Stimulating Factor
7
sargramostim
6
Vincristine
6
TPI-287
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
IL32 protein, human
×
CNS
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts